Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 1, 2024

Benefit-risk assessment of three oral Chinese patent medicines for activating blood and eliminating mass in treating primary liver cancer based on network Meta-analysis and multi-criteria decision analysis.

View Full Paper
Ask AI
Bookmark
Share

Authors

RZRongrong ZhangYFYu FuRZRuixia Zhao

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Zhang et al. (2024) studied this question.

synapsesocial.com/papers/68e62387b6db6435875b5feahttps://doi.org/10.19540/j.cnki.cjcmm.20240409.501
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Oral Chinese patent medicine combined with transarterial chemoembolization for the treatment of unresectable hepatocellular carcinoma: A Bayesian network meta-analysis2025
  2. 2Identifying the Well-suited Chinese Herbal Products for Hepatocellular Carcinoma (HCC) Patients in Terms of Hazard Ratio and Child-Pugh Score Improvement: A Frequentist Statistical Analysis Applying ‘Netmeta’2022
  3. 3Beneficial effects of proprietary Chinese medicines as adjuvant therapy in patients with advanced colorectal cancer: A meta-analysis2025
  4. 4Immune regulation and clinical response of Chinese herbal injections combined with TACE in hepatocellular carcinoma: a cumulative logit regression and Bayesian network meta-analysis2025 · 1 citations
  5. 5[Network Meta-analysis of Chinese patent medicines in treatment of chronic pulmonary heart disease].2024